AGITATION IN DELIRIUM MANAGEMENT MARKET ANALYSIS

Agitation In Delirium Management MarketSize and Trends

Global agitation in delirium management market is estimated to be valued at US$ 237.2 Mn in 2023, and is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030).

Figure 1. Global Agitation in Delirium Management Market Share (%), By Drug Type, 2023

Global Agitation in Delirium Management Market– Drivers

• Increasing incidence of delirium: The increasing incidence of delirium among patients admitted to intensive care unit (ICU) is expected to drive the global agitation in delirium management market growth over the forecast period. For instance, in September 2022, according to the data published by Hindwai, a a publisher of peer-reviewed, open access, scientific journals currently active in scientific, technical, and medical literature, the incidence of delirium was up to 46.3% among patients admitted to the ICU.

Figure 2. Global Agitation in Delirium Management Market Share (%), By Region, 2023

Global Agitation in Delirium Management Market - Key Trends

• Increasing product approval by regulatory authority: Increasing product approval by regulatory authority is expected to prpel the market growth. For instance, in June 2021, Alkermes plc, a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved LYBALVI, a combination of olanzapine and samidorphan, for the treatment of adults with schizophrenia or bipolar I disorder. LYBALVI is a once-daily, atypical antipsychotic that works as a maintenance monotherapy for the acute treatment of manic or mixed episodes or as an adjunct to lithium or valproate.